Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients
Achieving serum urate targets with urate-lowering therapy reduces the 5-year risk of major adverse cardiovascular events in gout patients.
2
In a study of 109,504 adults, those who reached urate levels below 6 mg/dL had a hazard ratio of 0.91 for cardiovascular events.
3
Patients achieving urate levels below 5 mg/dL showed an even stronger association, with a hazard ratio of 0.77 and a 3 percentage point survival difference.
4
The study highlights a potential link between gout flares, systemic inflammation, and cardiovascular risk, rather than urate lowering alone.
5
Despite adjustments, residual confounding may affect results, and fewer than one-third of patients achieved target urate levels within the first year.
